EPISODE · Jul 26, 2020 · 28 MIN
SARs CoV-2 (COVID19)
from Longevity Metrics · host William Brandenburg
Lecture Summary This lecture talks about my opinions and experience treating COVID19 in the outpatient, inpatient, and ICU setting. Key Points - Public health is always more important than clinical medicine for the health of any population. - So much information has changed so rapidly regarding COVID19, we need to focus on what really matters. - Everything about Remdesivir points to a drug that works very poorly or not at all. From my perspective it looks like the manufacturers are delaying the real evidence to try and make big bucks before the truth comes out. I predict no mortality benefit. - 80s are the new 90s for oxygen saturation. Consider proning patients early and for at least 16 hours a day if tolerated. References This lecture is for the most part based on my opinions and experiences. I do cite a few things in the text. But please take everything in this lecture as mostly my opinion! - CDC, available at https://www.cdc.gov/coronavirus/2019-ncov/index.html - WHO, available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAjwsO_4BRBBEiwAyagRTXlcLwmvRu9TKu22ZWDMcoK1zlS_IlUELlb6_1EdUcvuWtpKlJQnmxoCtx4QAvD_BwE - Beigel et al. Remdesivir RCT. NEJM. 2020 - My experience living through the past 7 months
Embed this episode
What this episode covers
Lecture Summary This lecture talks about my opinions and experience treating COVID19 in the outpatient, inpatient, and ICU setting. Key Points - Public health is always more important than clinical medicine for the health of any population. - So much information has changed so rapidly regarding COVID19, we need to focus on what really matters. - Everything about Remdesivir points to a drug that works very poorly or not at all. From my perspective it looks like the manufacturers are delaying ...
Ready to play
SARs CoV-2 (COVID19)
No transcript for this episode yet
Similar Episodes
No similar episodes found.